Comparative Pharmacology
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE ALLERGY versus HISPRIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FEXOFENADINE HYDROCHLORIDE ALLERGY versus HISPRIL.
FEXOFENADINE HYDROCHLORIDE ALLERGY vs HISPRIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fexofenadine is a selective peripheral H1-receptor antagonist that inhibits histamine release from mast cells and basophils.
HISPRIL (lisinopril) is an angiotensin-converting enzyme (ACE) inhibitor that blocks the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure and afterload.
60 mg orally twice daily or 180 mg orally once daily.
10 mg orally once daily, increased to 20 mg once daily after 2-4 weeks if needed.
None Documented
None Documented
Terminal elimination half-life is 14.4 hours in healthy adults. In renal impairment, half-life may be prolonged up to 59 hours.
The terminal elimination half-life of HISPRIL is approximately 12-15 hours in patients with normal renal function, supporting twice-daily dosing. In moderate to severe renal impairment (CrCl <30 mL/min), half-life is prolonged up to 30-40 hours, necessitating dose interval adjustment.
Primarily excreted unchanged in feces (80%) and urine (11%). Biliary excretion contributes to fecal elimination.
HISPRIL is predominantly excreted renally, with approximately 60-70% of an administered dose recovered unchanged in urine over 48 hours. Hepatic metabolism accounts for <10% of elimination, and fecal excretion contributes <5%.
Category A/B
Category C
Antihistamine
Antihistamine